(Q34191297)

31 July 2017

1 reference

title

Orlistat--a novel weight loss therapy (English)

1 reference

31 July 2017

K H Lucas

1

1 reference

31 July 2017

B Kaplan-Machlis

series ordinal

2

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 March 2001

1 reference

Annals of Pharmacotherapy

31 July 2017

published in

1 reference

31 July 2017

volume

35

1 reference

31 July 2017

issue

3

1 reference

31 July 2017

page(s)

314-328

1 reference

Varying body mass index cutoff points to describe overweight prevalence among U.S. adults: NHANES III (1988 to 1994).

31 July 2017

cites work

1 reference

Update on the pharmacotherapy of obesity

21 January 2018

1 reference

Current concepts in the pharmacological management of obesity

21 January 2018

1 reference

Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers

21 January 2018

1 reference

Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro 18–0647 (tetrahydrolipstatin)

21 January 2018

1 reference

Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group

21 January 2018

1 reference

Metabolic profiles of minimally absorbed orlistat in obese/overweight volunteers

21 January 2018

1 reference

Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study

21 January 2018

1 reference

Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial

21 January 2018

1 reference

Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group

21 January 2018

1 reference

Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults

21 January 2018

1 reference

Fat intake and food choices during weight reduction with diet, behavioural modification and a lipase inhibitor

21 January 2018

1 reference

Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice

21 January 2018

1 reference

Orlistat associated with hypertension

21 January 2018

1 reference

The Influence of Orlistat on the Pharmacokinetics and Pharmacodynamics of Glyburide in Healthy Volunteers

21 January 2018

1 reference

Olestra: assessing its potential to interact with drugs in the gastrointestinal tract

21 January 2018

1 reference

Modern medical management of obesity: the role of pharmaceutical intervention

21 January 2018

1 reference

Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity

21 January 2018

1 reference

Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine

21 January 2018

1 reference

Current estimates of the economic cost of obesity in the United States

21 January 2018

1 reference

Obesity, health services use, and health care costs among members of a health maintenance organization.

21 January 2018

1 reference

A risk-benefit assessment of anti-obesity drugs

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.19412

1 reference

31 July 2017

1 reference